Literature DB >> 21393407

Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma.

L C Hygino da Cruz1, I Rodriguez, R C Domingues, E L Gasparetto, A G Sorensen.   

Abstract

The current standard of care for newly diagnosed cases of high-grade glioma is surgical resection followed by RT with concurrent chemotherapy. The most widely used criteria for assessing treatment response are based on a 2D measurement of the enhancing area on MR imaging known as the Macdonald Criteria. Recently, nontumoral increases (pseudoprogression) and decreases (pseudoresponse) in enhancement have been found, and these can confuse outcome evaluation. Here we review pseudoprogression and pseudoresponse and describe how better understanding of these phenomena can aid interpretation.

Entities:  

Mesh:

Year:  2011        PMID: 21393407      PMCID: PMC7964401          DOI: 10.3174/ajnr.A2397

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  33 in total

1.  Pseudoprogression in glioblastoma.

Authors:  Marc C Chamberlain
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

2.  Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma.

Authors:  Christina Tsien; Craig J Galbán; Thomas L Chenevert; Timothy D Johnson; Daniel A Hamstra; Pia C Sundgren; Larry Junck; Charles R Meyer; Alnawaz Rehemtulla; Theodore Lawrence; Brian D Ross
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

3.  Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib.

Authors:  Elizabeth R Gerstner; Poe-Jou Chen; Patrick Y Wen; Rakesh K Jain; Tracy T Batchelor; Gregory Sorensen
Journal:  Neuro Oncol       Date:  2010-01-22       Impact factor: 12.300

4.  Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions.

Authors:  Pia C Sundgren; Xiaoying Fan; Patrick Weybright; Robert C Welsh; Ruth C Carlos; Myria Petrou; Paul E McKeever; Thomas L Chenevert
Journal:  Magn Reson Imaging       Date:  2006-09-18       Impact factor: 2.546

Review 5.  Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.

Authors:  Dieta Brandsma; Lukas Stalpers; Walter Taal; Peter Sminia; Martin J van den Bent
Journal:  Lancet Oncol       Date:  2008-05       Impact factor: 41.316

6.  Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression.

Authors:  Elizabeth R Gerstner; Margaret B McNamara; Andrew D Norden; Debra Lafrankie; Patrick Y Wen
Journal:  J Neurooncol       Date:  2009-02-17       Impact factor: 4.130

7.  Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.

Authors:  Walter Taal; Dieta Brandsma; Hein G de Bruin; Jacoline E Bromberg; Annemarie T Swaak-Kragten; Peter A E Sillevis Smitt; Corine A van Es; Martin J van den Bent
Journal:  Cancer       Date:  2008-07-15       Impact factor: 6.860

Review 8.  Pseudoprogression and pseudoresponse: challenges in brain tumor imaging.

Authors:  Jennifer L Clarke; Susan Chang
Journal:  Curr Neurol Neurosci Rep       Date:  2009-05       Impact factor: 5.081

9.  A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.

Authors:  A Gregory Sorensen; Tracy T Batchelor; Wei-Ting Zhang; Poe-Jou Chen; Priscilla Yeo; Meiyun Wang; Dominique Jennings; Patrick Y Wen; Johanna Lahdenranta; Marek Ancukiewicz; Emmanuelle di Tomaso; Dan G Duda; Rakesh K Jain
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

Review 10.  VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.

Authors:  Elizabeth R Gerstner; Dan G Duda; Emmanuelle di Tomaso; Peter A Ryg; Jay S Loeffler; A Gregory Sorensen; Percy Ivy; Rakesh K Jain; Tracy T Batchelor
Journal:  Nat Rev Clin Oncol       Date:  2009-04       Impact factor: 66.675

View more
  179 in total

1.  Bevacizumab: radiation combination produces restricted diffusion on brain MRI.

Authors:  John R Hesselink; Matthew J Barkovich; Tyler M Seibert; Nikdokht Farid; Karra A Muller; Kevin T Murphy; Santosh Kesari
Journal:  CNS Oncol       Date:  2014

2.  Early Biomarkers from Conventional and Delayed-Contrast MRI to Predict the Response to Bevacizumab in Recurrent High-Grade Gliomas.

Authors:  D Daniels; D Guez; D Last; C Hoffmann; D Nass; A Talianski; G Tsarfaty; S Salomon; A A Kanner; D T Blumenthal; F Bokstein; S Harnof; D Yekutieli; S Zamir; Z R Cohen; L Zach; Y Mardor
Journal:  AJNR Am J Neuroradiol       Date:  2016-07-07       Impact factor: 3.825

3.  Serum concentrations of glial fibrillary acidic protein (GFAP) do not indicate tumor recurrence in patients with glioblastoma.

Authors:  Julia-Mareen Vietheer; Johannes Rieger; Marlies Wagner; Christian Senft; Julia Tichy; Christian Foerch
Journal:  J Neurooncol       Date:  2017-07-17       Impact factor: 4.130

4.  Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.

Authors:  Jerrold L Boxerman; Zheng Zhang; Yair Safriel; Mykol Larvie; Bradley S Snyder; Rajan Jain; T Linda Chi; A Gregory Sorensen; Mark R Gilbert; Daniel P Barboriak
Journal:  Neuro Oncol       Date:  2013-06-19       Impact factor: 12.300

5.  Diagnostic Accuracy of Centrally Restricted Diffusion in the Differentiation of Treatment-Related Necrosis from Tumor Recurrence in High-Grade Gliomas.

Authors:  N Zakhari; M S Taccone; C Torres; S Chakraborty; J Sinclair; J Woulfe; G H Jansen; T B Nguyen
Journal:  AJNR Am J Neuroradiol       Date:  2017-12-07       Impact factor: 3.825

Review 6.  Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis.

Authors:  P D Delgado-López; E Riñones-Mena; E M Corrales-García
Journal:  Clin Transl Oncol       Date:  2017-12-07       Impact factor: 3.405

7.  Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas.

Authors:  Andrew L Lin; Jingxia Liu; John Evans; Eric C Leuthardt; Keith M Rich; Ralph G Dacey; Joshua L Dowling; Albert H Kim; Gregory J Zipfel; Robert L Grubb; Jiayi Huang; Clifford G Robinson; Joseph R Simpson; Gerald P Linette; Michael R Chicoine; David D Tran
Journal:  Neuro Oncol       Date:  2013-11-26       Impact factor: 12.300

8.  Biophysical Modeling of In Vivo Glioma Response After Whole-Brain Radiation Therapy in a Murine Model of Brain Cancer.

Authors:  David A Hormuth; Jared A Weis; Stephanie L Barnes; Michael I Miga; Vito Quaranta; Thomas E Yankeelov
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-12-13       Impact factor: 7.038

9.  Dynamic Contrast-Enhanced MRI in Patients with Brain Metastases Undergoing Laser Interstitial Thermal Therapy: A Pilot Study.

Authors:  J I Traylor; D C A Bastos; D Fuentes; M Muir; R Patel; V A Kumar; R J Stafford; G Rao; S S Prabhu
Journal:  AJNR Am J Neuroradiol       Date:  2019-08-01       Impact factor: 3.825

Review 10.  Restriction spectrum imaging: An evolving imaging biomarker in prostate MRI.

Authors:  Ryan L Brunsing; Natalie M Schenker-Ahmed; Nathan S White; J Kellogg Parsons; Christopher Kane; Joshua Kuperman; Hauke Bartsch; Andrew Karim Kader; Rebecca Rakow-Penner; Tyler M Seibert; Daniel Margolis; Steven S Raman; Carrie R McDonald; Nikdokht Farid; Santosh Kesari; Donna Hansel; Ahmed Shabaik; Anders M Dale; David S Karow
Journal:  J Magn Reson Imaging       Date:  2016-08-16       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.